Can a targeted pill combo tame acute myeloid leukemia without harsh chemo?

NCT ID NCT07773909

NEW Completed Disease control Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This trial tests whether a combination of venetoclax (a targeted pill) plus a hypomethylating agent (azacitidine or decitabine) can help adults with newly diagnosed acute myeloid leukemia who are not eligible for intensive chemotherapy. The study includes older patients, those with health issues, and younger patients who cannot afford intensive treatment. After one 28-day cycle, researchers will check bone marrow to see if the cancer goes into remission, and they will also monitor blood counts, side effects, and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax combined with a hypomethylating agent (azacitidine or decitabine), plus voriconazole as antifungal prophylaxis
What this could lead to: If successful, this could offer a gentler, effective treatment option for AML patients who cannot tolerate intensive chemotherapy, including those with financial barriers.
What could go wrong: This is a small, single-center study with only 24 participants, so results may not apply broadly. The treatment can cause side effects, and the short follow-up limits conclusions about long-term benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Dhaka Medical College Hospital

Dhaka, Dhaka Division, 1000, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.